Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Clinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study

Full metadata record
DC Field Value Language
dc.contributor.authorKwon, Seong Young-
dc.contributor.authorLee, Sang-Woo-
dc.contributor.authorKong, Eun Jung-
dc.contributor.authorKim, Keunyoung-
dc.contributor.authorKim, Byung Il-
dc.contributor.authorKim, Jahae-
dc.contributor.authorKim, Heeyoung-
dc.contributor.authorPark, Seol Hoon-
dc.contributor.authorPark, Jisun-
dc.contributor.authorPark, Hye Lim-
dc.contributor.authorOh, So Won-
dc.contributor.authorWon, Kyoung Sook-
dc.contributor.authorRyu, Young Hoon-
dc.contributor.authorYoon, Joon-Kee-
dc.contributor.authorLee, Soo Jin-
dc.contributor.authorLee, Jong Jin-
dc.contributor.authorChong, Ari-
dc.contributor.authorJeong, Young Jin-
dc.contributor.authorJeong, Ju Hye-
dc.contributor.authorCho, Young Seok-
dc.contributor.authorCho, Arthur-
dc.contributor.authorCheon, Gi Jeong-
dc.contributor.authorChoi, Eun Kyoung-
dc.contributor.authorHwang, Jae Pil-
dc.contributor.authorBae, Sang Kyun-
dc.date.accessioned2021-08-11T08:37:26Z-
dc.date.available2021-08-11T08:37:26Z-
dc.date.issued2020-03-
dc.identifier.issn1619-7070-
dc.identifier.issn1619-7089-
dc.identifier.urihttps://scholarworks.bwise.kr/sch/handle/2021.sw.sch/3056-
dc.description.abstractPurpose We investigated whether predictive clinicopathologic factors can be affected by different response criteria and how the clinical usefulness of radioactive iodine (RAI) therapy should be evaluated considering variable factors in patients with differentiated thyroid carcinoma (DTC). Methods A total of 1563 patients with DTC who underwent first RAI therapy after total or near total thyroidectomy were retrospectively enrolled from 25 hospitals. Response to therapy was evaluated with two different protocols based on combination of biochemical and imaging studies: (1) serum thyroglobulin (Tg) and neck ultrasonography (US) and (2) serum Tg, neck US, and radioiodine scan. The responses to therapy were classified into excellent and non-excellent or acceptable and non-acceptable to minimize the effect of non-specific imaging findings. We investigated which factors were associated with response to therapy depending on the follow-up protocols as well as response classifications. Multivariate logistic regression analysis was performed to identify factors significantly predicting response to therapy. Results The proportion of patients in the excellent response group significantly decreased from 76.5 to 59.6% when radioiodine scan was added to the follow-up protocol (P < 0.001). Preparation method (recombinant human TSH vs. thyroid hormone withdrawal) was a significant factor for excellent response prediction evaluated with radioiodine scan (OR 2.129; 95% CI 1.687-2.685; P < 0.001) but was not for other types of response classifications. Administered RAI activity, which was classified as low (1.11 GBq) or high (3.7 GBq or higher), significantly predicted both excellent and acceptable responses regardless of the follow-up protocol. Conclusions The clinical impact of factors related to response prediction differed depending on the follow-up protocol or classification of response criteria. A high administered activity of RAI was a significant factor predicting a favorable response to therapy regardless of the follow-up protocol or classification of response criteria.-
dc.format.extent11-
dc.language영어-
dc.language.isoENG-
dc.publisherSpringer Verlag-
dc.titleClinicopathologic risk factors of radioactive iodine therapy based on response assessment in patients with differentiated thyroid cancer: a multicenter retrospective cohort study-
dc.typeArticle-
dc.publisher.location미국-
dc.identifier.doi10.1007/s00259-019-04634-8-
dc.identifier.wosid000517882500011-
dc.identifier.bibliographicCitationEuropean Journal of Nuclear Medicine and Molecular Imaging, v.47, no.3, pp 561 - 571-
dc.citation.titleEuropean Journal of Nuclear Medicine and Molecular Imaging-
dc.citation.volume47-
dc.citation.number3-
dc.citation.startPage561-
dc.citation.endPage571-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalResearchAreaRadiology, Nuclear Medicine & Medical Imaging-
dc.relation.journalWebOfScienceCategoryRadiology, Nuclear Medicine & Medical Imaging-
dc.subject.keywordPlusASSOCIATION MANAGEMENT GUIDELINES-
dc.subject.keywordPlusRADIOIODINE REMNANT ABLATION-
dc.subject.keywordPlusADULT PATIENTS-
dc.subject.keywordPlusPAPILLARY-
dc.subject.keywordPlusSURVIVAL-
dc.subject.keywordPlusNODULES-
dc.subject.keywordAuthorDifferentiated thyroid carcinoma-
dc.subject.keywordAuthorRadioactive iodine therapy-
dc.subject.keywordAuthorRecombinant human thyrotropin-
dc.subject.keywordAuthorResponse to therapy-
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Radiology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Altmetrics

Total Views & Downloads

BROWSE